Physician profile
Eugene A Ryfinski
NPI 1073581625
$3,237.02
in general payments reported to CMS, 2019-2025
27 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $181 · 2021: $477 · 2022: $456 · 2023: $397 · 2024: $403 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $741.52 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $288.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $267.21 | 2019-2023 | |
| Lilly USA, LLC | $183.64 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.36 | 2019-2025 | Xifaxan, Relistor |
| Abbott Laboratories | $166.95 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $162.70 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $148.67 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $132.95 | 2019-2025 | |
| Exact Sciences Corporation | $132.04 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $129.38 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.42 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $85.38 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceuticals, INC. | $74.22 | 2021 | |
| Dexcom, INC. | $61.32 | 2024-2025 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50.82 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.54 | 2025 | Caplyta |
| Boston Scientific Corporation | $42.26 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $40.95 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $29.23 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $28.82 | 2021-2022 | |
| Amarin Pharma, INC. | $28.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.36 | 2021-2023 | Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $17.94 | 2025 | |
| Collegium Pharmaceutical, INC. | $17.76 | 2024 | Belbuca |
| Hikma Pharmaceuticals USA | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Ryfinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.